20
Participants
Start Date
July 25, 2023
Primary Completion Date
August 27, 2026
Study Completion Date
August 27, 2026
teplizumab
CD3-directed humanized monoclonal antibody
UBMD Pediactrics Site Number : 105, Buffalo
Children's Hospital of Philadelphia Site Number : 108, Philadelphia
Centricity Research Site Number : 104, Columbus
Vanderbilt Univerity Medical Center Site Number : 109, Nashville
Indianapolis University Health Riley Hospital for Children Site Number : 110, Indianapolis
Sanford Diabetes and Thyroid Clinic Site Number : 106, Sioux Falls
Barbara Davis Center for Diabetes Site Number : 102, Aurora
UCSF Medical Center Site Number : 107, San Francisco
MulitCare Institute for Research & Innovation Site Number : 103, Tacoma
Yale University School of Medicine Site Number : 101, New Haven
Provention Bio, a Sanofi Company
INDUSTRY